LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose ...

REGENERON PHARMACEUTICALS ($REGN) is expected to release its quarterly earnings data on Tuesday, February 4th before market open. Analysts are expecting revenue of ...

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...

In the pre-market hours, Regeneron's stock is trading at $695, down 0.27 percent on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not ...

Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 10 trades. If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened ...

During the last three months, 22 analysts shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN), revealing diverse outlooks from bullish to bearish. Summarizing their recent ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN), revealing diverse outlooks from bullish to bearish. The table below offers a ...

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician ...

Regeneron (REGN) Pharmaceuticals announced positive Phase 2 results for two novel monoclonal antibodies targeting distinct domains of Factor XI. REGN7508 is designed to maximize anticoagulant ...

Our analysis of options history for Regeneron Pharmaceuticals (NASDAQ:REGN) revealed 10 unusual trades. Delving into the details, we found 30% of traders were bullish, while 50% showed bearish ...